dc.contributor.author
Fischer, Hendrik S.
dc.contributor.author
Reibel, Nora J.
dc.contributor.author
Bührer, Christoph
dc.contributor.author
Dame, Christof
dc.date.accessioned
2021-09-28T08:03:30Z
dc.date.available
2021-09-28T08:03:30Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/32082
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-31810
dc.description.abstract
A meta-analysis update of randomized controlled trials investigating recombinant human erythropoietin suggests improved neurodevelopmental outcome in preterm infants. There was substantial heterogeneity, which could be ascribed to a single trial. Exclusion of this trial featuring a high risk of bias abolished heterogeneity and any effects of recombinant human erythropoietin treatment.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
erythropoietin
en
dc.subject
meta-analysis
en
dc.subject
neurodevelopment
en
dc.subject
neuroprotection
en
dc.subject
VLBW and ELBW infants
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Prophylactic Erythropoietin for Neuroprotection in Very Preterm Infants: A Meta-Analysis Update
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
657228
dcterms.bibliographicCitation.doi
10.3389/fped.2021.657228
dcterms.bibliographicCitation.journaltitle
Frontiers in Pediatrics
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.volume
9
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34095027
dcterms.isPartOf.eissn
2296-2360
